RBC Capital upgraded MannKind (MNKD) to Outperform from Sector Perform with a price target of $10, up from $7. The firm cites MannKind’s “diversifying dimensions of valuation support and upside potential” for the upgrade. RBC models Tyvaso DPI royalty revenue opportunity in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis via advancing the company’s TETON programs with partner United Therapeutics (UTHR). It estimates up to $200M in royalties from IPF and PPF per year for MannKind, contributing to peak Tyvaso DPI royalty revenues of $300M in 2030, accounting for 48% of the stock’s valuation. RBC also sees additive value from MannKind’s emerging orphan lung pipeline.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind upgraded to Outperform from Sector Perform at RBC Capital
- MannKind announces exchange of convertible notes for stock, cash
- MannKind reports six-month results from Phase 3 INHALE-1 trial
- MannKind, Cipla: CDSCO in India approves Afrezza Inhalation Powder in India
- Leerink healthcare analysts hold an analyst/industry conference call